和铂医药：行使认股权证，获Spruce约3.8%股份

Group 1 - The core announcement is that the company, Heptares Therapeutics, exercised warrants under a licensing and collaboration agreement with Spruce Biosciences Inc. [1] - The company and its subsidiary, HBM Alpha Therapeutics, will hold approximately 3.8% of the total shares outstanding and about 3.1% of fully diluted shares of Spruce after exercising the warrants on January 19, 2026 [1] - The announcement includes a caution for shareholders and potential investors to act prudently, as there is no guarantee of successful development or eventual sales of any candidate products mentioned [1]